{"id":6935,"date":"2013-03-06T22:00:00","date_gmt":"2013-03-06T22:00:00","guid":{"rendered":"https:\/\/www.nicox.com\/presentation-des-resultats-de-phase-2b-pour-le-latanoprostene-bunod-le-candidat-medicament-ciblant-le-glaucome\/"},"modified":"2013-03-06T22:00:00","modified_gmt":"2013-03-06T22:00:00","slug":"presentation-des-resultats-de-phase-2b-pour-le-latanoprostene-bunod-le-candidat-medicament-ciblant-le-glaucome","status":"publish","type":"post","link":"https:\/\/www.nicox.com\/fr\/presentation-des-resultats-de-phase-2b-pour-le-latanoprostene-bunod-le-candidat-medicament-ciblant-le-glaucome\/","title":{"rendered":"Pr\u00e9sentation des r\u00e9sultats de phase 2b pour le latanoprost\u00e8ne bunod, le candidat-m\u00e9dicament ciblant le glaucome"},"content":{"rendered":"

7 mars 2013<\/p>\n

Les r\u00e9sultats de phase 2b pour le latanoprost\u00e8ne bunod (pr\u00e9c\u00e9demment appel\u00e9 BOL-303259-X) ont \u00e9t\u00e9 pr\u00e9sent\u00e9s \u00e0 l\u2019American Glaucoma Society 23rd Annual Meeting le 2 mars par Robert N. Weinreb, M.D., Professeur \u00e9m\u00e9rite et Pr\u00e9sident d’ophtalmologie de l’Universit\u00e9 de Californie \u00e0 San Diego et Directeur du Shiley Eye Center et du Hamilton Glaucoma Center. <\/strong><\/p>\n

Le latanoprost\u00e8ne bunod, un analogue de la prostaglandine F2-alpha donneur d\u2019oxyde nitrique donn\u00e9 en licence par Nicox \u00e0 Bausch + Lomb, a \u00e9t\u00e9 d\u00e9velopp\u00e9 pour la r\u00e9duction de la pression intraoculaire (PIO) chez des patients souffrant de glaucome ou d\u2019hypertension oculaire. Lors de cette \u00e9tude de d\u00e9termination de dose, il a \u00e9t\u00e9 montr\u00e9 que le latanoprost\u00e8ne bunod induisait une diminution coh\u00e9rente et dose-d\u00e9pendante de la PIO. <\/strong><\/p>\n

Le glaucome regroupe des pathologies oculaires pouvant entra\u00eener une perte de la vision p\u00e9riph\u00e9rique, voire une c\u00e9cit\u00e9 totale \u00e0 terme. Le glaucome est fr\u00e9quemment li\u00e9 \u00e0 une pression anormalement \u00e9lev\u00e9e \u00e0 l\u2019int\u00e9rieur de l\u2019\u0153il (pression intraoculaire, PIO), en raison de l\u2019obstruction ou du mauvais fonctionnement des syst\u00e8mes de drainage de l\u2019\u0153il. Plusieurs \u00e9tudes de grande ampleur ont d\u00e9montr\u00e9 qu\u2019une r\u00e9duction de PIO pouvait emp\u00eacher la progression du glaucome \u00e0 des stades pr\u00e9coces ou avanc\u00e9s de la maladie. Une part significative des patients pr\u00e9sentant une PIO \u00e9lev\u00e9e a besoin de plus d\u2019un m\u00e9dicament pour maintenir leur PIO aux niveaux de pression cibl\u00e9s, soulignant le besoin de traitements plus efficaces.<\/p>\n

La pr\u00e9sentation a montr\u00e9 l\u2019efficacit\u00e9 du latanoprost\u00e8ne bunod dans la r\u00e9duction de la pression intraoculaire (PIO) de mani\u00e8re dose d\u00e9pendante sur les doses test\u00e9es. Il a \u00e9t\u00e9 \u00e9galement montr\u00e9 que le latanoprost\u00e8ne bunod 0.024% administr\u00e9 une fois par jour induisait une r\u00e9duction statistiquement significative de la PIO sup\u00e9rieure \u00e0 celle observ\u00e9e avec le latanoprost, avec un profil de tol\u00e9rance similaire.<\/p>\n

Bausch + Lomb a initi\u00e9 cette \u00e9tude de phase 2b randomis\u00e9e et \u00e0 simple insu (\u00e0 l\u2019insu de l\u2019investigateur) en novembre 2010 dans le but d\u2019identifier la dose du latanoprost\u00e8ne bunod la plus efficace et la plus s\u00fbre pour la r\u00e9duction de la PIO. 413 patients ont \u00e9t\u00e9 recrut\u00e9s dans 23 sites aux Etats-Unis et en Europe. Les patients ont \u00e9t\u00e9 randomis\u00e9s pour recevoir du latanoprost\u00e8ne bunod (plusieurs concentrations) ou du Xalatan\u00ae 0,005% (latanoprost) une fois par jour, le soir, pendant 28 jours. L\u2019\u00e9tude de phase 2b a atteint le crit\u00e8re principal d\u2019efficacit\u00e9 qui \u00e9tait la r\u00e9duction de la pression intra-oculaire (PIO) diurne moyenne au 28\u00e8me jour. Des r\u00e9sultats positifs ont \u00e9galement \u00e9t\u00e9 obtenus sur plusieurs crit\u00e8res d\u2019\u00e9valuation secondaires.<\/p>\n

Dans le contexte des r\u00e9sultats positifs de phase 2b, Bausch + Lomb a initi\u00e9 son programme d\u2019\u00e9tudes cliniques de phase 3 du latanoprost\u00e8ne bunod en janvier 2013. Ce programme d\u2019\u00e9tudes pivots de phase 3 comprend deux \u00e9tudes individuelles randomis\u00e9es, multicentriques, men\u00e9es \u00e0 double-insu et en groupes parall\u00e8les. Ces deux \u00e9tudes, appel\u00e9es APOLLO et LUNAR, visent \u00e0 comparer, chez des patients souffrant de glaucome \u00e0 angle ouvert ou d\u2019hypertension oculaire, l\u2019efficacit\u00e9 sur la r\u00e9duction de la PIO et la s\u00e9curit\u00e9 d\u2019emploi du latanoprost\u00e8ne bunod (administr\u00e9 une fois par jour) avec celles du mal\u00e9ate de timolol 0,5% (administr\u00e9 deux fois par jour).<\/p>\n

Plus d\u2019informations:<\/strong><\/p>\n

\u2022 A propos de notre partenariat avec Bausch + Lomb<\/a><\/p>\n

\u2022 Bausch + Lomb initie un programme d\u2019\u00e9tudes de phase 3 pour un candidat-m\u00e9dicament ciblant le glaucome et sous licence Nicox<\/a><\/p>\n

\u2022 Le candidat-m\u00e9dicament de NicOx et Bausch + Lomb BOL-303259-X ciblant le glaucome a atteint le crit\u00e8re d\u2019\u00e9valuation principal de l\u2019\u00e9tude de phase 2b<\/a><\/p>\n","protected":false},"excerpt":{"rendered":"

Les r\u00e9sultats de phase 2b pour le latanoprost\u00e8ne bunod ont \u00e9t\u00e9 pr\u00e9sent\u00e9s \u00e0 l\u2019American Glaucoma Society 23rd Annual Meeting<\/i> le 2 mars par le Dr. Robert N. Weinreb.<\/p>\n","protected":false},"author":7,"featured_media":0,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"_acf_changed":false,"footnotes":""},"categories":[32,16],"tags":[],"class_list":["post-6935","post","type-post","status-publish","format-standard","hentry","category-actualites","category-actualites-et-media"],"acf":[],"yoast_head":"\nPr\u00e9sentation des r\u00e9sultats de phase 2b pour le latanoprost\u00e8ne bunod, le candidat-m\u00e9dicament ciblant le glaucome - Nicox<\/title>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/www.nicox.com\/fr\/presentation-des-resultats-de-phase-2b-pour-le-latanoprostene-bunod-le-candidat-medicament-ciblant-le-glaucome\/\" \/>\n<meta property=\"og:locale\" content=\"fr_FR\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"Pr\u00e9sentation des r\u00e9sultats de phase 2b pour le latanoprost\u00e8ne bunod, le candidat-m\u00e9dicament ciblant le glaucome - Nicox\" \/>\n<meta property=\"og:description\" content=\"Les r\u00e9sultats de phase 2b pour le latanoprost\u00e8ne bunod ont \u00e9t\u00e9 pr\u00e9sent\u00e9s \u00e0 l\u2019American Glaucoma Society 23rd Annual Meeting le 2 mars par le Dr. Robert N. Weinreb.\" \/>\n<meta property=\"og:url\" content=\"https:\/\/www.nicox.com\/fr\/presentation-des-resultats-de-phase-2b-pour-le-latanoprostene-bunod-le-candidat-medicament-ciblant-le-glaucome\/\" \/>\n<meta property=\"og:site_name\" content=\"Nicox\" \/>\n<meta property=\"article:published_time\" content=\"2013-03-06T22:00:00+00:00\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:label1\" content=\"\u00c9crit par\" \/>\n\t<meta name=\"twitter:data1\" content=\"\" \/>\n\t<meta name=\"twitter:label2\" content=\"Dur\u00e9e de lecture estim\u00e9e\" \/>\n\t<meta name=\"twitter:data2\" content=\"3 minutes\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\\\/\\\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\\\/\\\/www.nicox.com\\\/fr\\\/presentation-des-resultats-de-phase-2b-pour-le-latanoprostene-bunod-le-candidat-medicament-ciblant-le-glaucome\\\/#article\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/www.nicox.com\\\/fr\\\/presentation-des-resultats-de-phase-2b-pour-le-latanoprostene-bunod-le-candidat-medicament-ciblant-le-glaucome\\\/\"},\"author\":{\"name\":\"\",\"@id\":\"\"},\"headline\":\"Pr\u00e9sentation des r\u00e9sultats de phase 2b pour le latanoprost\u00e8ne bunod, le candidat-m\u00e9dicament ciblant le glaucome\",\"datePublished\":\"2013-03-06T22:00:00+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\\\/\\\/www.nicox.com\\\/fr\\\/presentation-des-resultats-de-phase-2b-pour-le-latanoprostene-bunod-le-candidat-medicament-ciblant-le-glaucome\\\/\"},\"wordCount\":647,\"publisher\":{\"@id\":\"https:\\\/\\\/www.nicox.com\\\/fr\\\/#organization\"},\"articleSection\":[\"Actualit\u00e9s\",\"Actualit\u00e9s et M\u00e9dia\"],\"inLanguage\":\"fr-FR\"},{\"@type\":\"WebPage\",\"@id\":\"https:\\\/\\\/www.nicox.com\\\/fr\\\/presentation-des-resultats-de-phase-2b-pour-le-latanoprostene-bunod-le-candidat-medicament-ciblant-le-glaucome\\\/\",\"url\":\"https:\\\/\\\/www.nicox.com\\\/fr\\\/presentation-des-resultats-de-phase-2b-pour-le-latanoprostene-bunod-le-candidat-medicament-ciblant-le-glaucome\\\/\",\"name\":\"Pr\u00e9sentation des r\u00e9sultats de phase 2b pour le latanoprost\u00e8ne bunod, le candidat-m\u00e9dicament ciblant le glaucome - Nicox\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/www.nicox.com\\\/fr\\\/#website\"},\"datePublished\":\"2013-03-06T22:00:00+00:00\",\"inLanguage\":\"fr-FR\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\\\/\\\/www.nicox.com\\\/fr\\\/presentation-des-resultats-de-phase-2b-pour-le-latanoprostene-bunod-le-candidat-medicament-ciblant-le-glaucome\\\/\"]}]},{\"@type\":\"WebSite\",\"@id\":\"https:\\\/\\\/www.nicox.com\\\/fr\\\/#website\",\"url\":\"https:\\\/\\\/www.nicox.com\\\/fr\\\/\",\"name\":\"Nicox\",\"description\":\"Visible Science\",\"publisher\":{\"@id\":\"https:\\\/\\\/www.nicox.com\\\/fr\\\/#organization\"},\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\\\/\\\/www.nicox.com\\\/fr\\\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"fr-FR\"},{\"@type\":\"Organization\",\"@id\":\"https:\\\/\\\/www.nicox.com\\\/fr\\\/#organization\",\"name\":\"Nicox\",\"url\":\"https:\\\/\\\/www.nicox.com\\\/fr\\\/\",\"logo\":{\"@type\":\"ImageObject\",\"inLanguage\":\"fr-FR\",\"@id\":\"https:\\\/\\\/www.nicox.com\\\/fr\\\/#\\\/schema\\\/logo\\\/image\\\/\",\"url\":\"\",\"contentUrl\":\"\",\"caption\":\"Nicox\"},\"image\":{\"@id\":\"https:\\\/\\\/www.nicox.com\\\/fr\\\/#\\\/schema\\\/logo\\\/image\\\/\"}},{\"@type\":\"Person\",\"@id\":\"\"}]}<\/script>\n<!-- \/ Yoast SEO plugin. -->","yoast_head_json":{"title":"Pr\u00e9sentation des r\u00e9sultats de phase 2b pour le latanoprost\u00e8ne bunod, le candidat-m\u00e9dicament ciblant le glaucome - Nicox","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/www.nicox.com\/fr\/presentation-des-resultats-de-phase-2b-pour-le-latanoprostene-bunod-le-candidat-medicament-ciblant-le-glaucome\/","og_locale":"fr_FR","og_type":"article","og_title":"Pr\u00e9sentation des r\u00e9sultats de phase 2b pour le latanoprost\u00e8ne bunod, le candidat-m\u00e9dicament ciblant le glaucome - Nicox","og_description":"Les r\u00e9sultats de phase 2b pour le latanoprost\u00e8ne bunod ont \u00e9t\u00e9 pr\u00e9sent\u00e9s \u00e0 l\u2019American Glaucoma Society 23rd Annual Meeting le 2 mars par le Dr. Robert N. Weinreb.","og_url":"https:\/\/www.nicox.com\/fr\/presentation-des-resultats-de-phase-2b-pour-le-latanoprostene-bunod-le-candidat-medicament-ciblant-le-glaucome\/","og_site_name":"Nicox","article_published_time":"2013-03-06T22:00:00+00:00","twitter_card":"summary_large_image","twitter_misc":{"\u00c9crit par":"","Dur\u00e9e de lecture estim\u00e9e":"3 minutes"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/www.nicox.com\/fr\/presentation-des-resultats-de-phase-2b-pour-le-latanoprostene-bunod-le-candidat-medicament-ciblant-le-glaucome\/#article","isPartOf":{"@id":"https:\/\/www.nicox.com\/fr\/presentation-des-resultats-de-phase-2b-pour-le-latanoprostene-bunod-le-candidat-medicament-ciblant-le-glaucome\/"},"author":{"name":"","@id":""},"headline":"Pr\u00e9sentation des r\u00e9sultats de phase 2b pour le latanoprost\u00e8ne bunod, le candidat-m\u00e9dicament ciblant le glaucome","datePublished":"2013-03-06T22:00:00+00:00","mainEntityOfPage":{"@id":"https:\/\/www.nicox.com\/fr\/presentation-des-resultats-de-phase-2b-pour-le-latanoprostene-bunod-le-candidat-medicament-ciblant-le-glaucome\/"},"wordCount":647,"publisher":{"@id":"https:\/\/www.nicox.com\/fr\/#organization"},"articleSection":["Actualit\u00e9s","Actualit\u00e9s et M\u00e9dia"],"inLanguage":"fr-FR"},{"@type":"WebPage","@id":"https:\/\/www.nicox.com\/fr\/presentation-des-resultats-de-phase-2b-pour-le-latanoprostene-bunod-le-candidat-medicament-ciblant-le-glaucome\/","url":"https:\/\/www.nicox.com\/fr\/presentation-des-resultats-de-phase-2b-pour-le-latanoprostene-bunod-le-candidat-medicament-ciblant-le-glaucome\/","name":"Pr\u00e9sentation des r\u00e9sultats de phase 2b pour le latanoprost\u00e8ne bunod, le candidat-m\u00e9dicament ciblant le glaucome - Nicox","isPartOf":{"@id":"https:\/\/www.nicox.com\/fr\/#website"},"datePublished":"2013-03-06T22:00:00+00:00","inLanguage":"fr-FR","potentialAction":[{"@type":"ReadAction","target":["https:\/\/www.nicox.com\/fr\/presentation-des-resultats-de-phase-2b-pour-le-latanoprostene-bunod-le-candidat-medicament-ciblant-le-glaucome\/"]}]},{"@type":"WebSite","@id":"https:\/\/www.nicox.com\/fr\/#website","url":"https:\/\/www.nicox.com\/fr\/","name":"Nicox","description":"Visible Science","publisher":{"@id":"https:\/\/www.nicox.com\/fr\/#organization"},"potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/www.nicox.com\/fr\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"fr-FR"},{"@type":"Organization","@id":"https:\/\/www.nicox.com\/fr\/#organization","name":"Nicox","url":"https:\/\/www.nicox.com\/fr\/","logo":{"@type":"ImageObject","inLanguage":"fr-FR","@id":"https:\/\/www.nicox.com\/fr\/#\/schema\/logo\/image\/","url":"","contentUrl":"","caption":"Nicox"},"image":{"@id":"https:\/\/www.nicox.com\/fr\/#\/schema\/logo\/image\/"}},{"@type":"Person","@id":""}]}},"_links":{"self":[{"href":"https:\/\/www.nicox.com\/fr\/wp-json\/wp\/v2\/posts\/6935","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/www.nicox.com\/fr\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/www.nicox.com\/fr\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/www.nicox.com\/fr\/wp-json\/wp\/v2\/users\/7"}],"replies":[{"embeddable":true,"href":"https:\/\/www.nicox.com\/fr\/wp-json\/wp\/v2\/comments?post=6935"}],"version-history":[{"count":0,"href":"https:\/\/www.nicox.com\/fr\/wp-json\/wp\/v2\/posts\/6935\/revisions"}],"wp:attachment":[{"href":"https:\/\/www.nicox.com\/fr\/wp-json\/wp\/v2\/media?parent=6935"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/www.nicox.com\/fr\/wp-json\/wp\/v2\/categories?post=6935"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/www.nicox.com\/fr\/wp-json\/wp\/v2\/tags?post=6935"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}